Evonik Expands Biomaterials Portfolio through JeNaCell Acquisition

Published on: 

Evonik has acquired the German biotech company JeNaCell, expanding its biomaterials portfolio.

Evonik has reported, in an Aug. 2, 2021 press release, that it has acquired the German biotech company JeNaCell, expanding its biomaterials portfolio for new medical device markets. The JeNaCell employees will continue to work at the development and production site based in Jena, Germany.

“JeNaCell has developed one of the most innovative biomaterials for medical device technologies. With the help of the creativity and expertise of JeNaCell's specialists, we will ensure that even more patients benefit from these products in the future,” said Thomas Riermeier, head of Evonik’s Health Care business line, in the press release. “The acquisition will help us to further strengthen our position as an innovation hub for the world’s leading medical technology companies.”

“The acquisition by Evonik is a quantum leap for JeNaCell to realize the full potential of our innovative technology,” added Dana Kralisch, CEO and co-founder of JeNaCell, in the press release. “We are excited to have found a strong and trusted partner to develop our technology platform and a new home for our passionate team of experts. Together, we will expand our customer base and explore new application areas.”


“JeNaCell is a great example for the innovation strength and the value that startups can bring to corporations,” said Bernhard Mohr, head of Evonik Venture Capital, in the press release. “We recognized the importance of the industry shift to nature-identical materials early on and are very happy to have supported the development of this technology with our investment.”

Source: Evonik